Design and Manufacture of Drug Delivery Platforms

在评估的早期阶段，药物通常只有少量可用。由于没有足够的材料对产品形式进行多次迭代，因此缺乏可用性给试图评估产品的药代动力学和功效带来了困难。在了解API的分子结构如何用于预测关键行为（包括log P，溶解度和pKa）以及如何使用给药片剂或植入物的配方设计和/或几何形状来控制药物溶出率方面的最新进展，将结合产生一个设计系统，该系统将能够快速优化3D打印固体剂型，为临床试验和早期评估做准备。

Drugs in the early stages of assessment are usually only available in small amounts. This lack of availability presents difficulties when attempting to assess the pharmacokinetics and the efficacy of a product, since one does not have sufficient material to iterate many times over product form. Recent developments in understanding how the molecular structure of an API can be used to predict key behaviours including log P, solubility and pKa, and how the formulation design and/or geometry of a drug delivery tablet or implant can be used to control drug dissolution rate, will be combined to produce a design system that will enable rapid optimisation of 3D printable solid dosage forms ready for clinical trial and early stage assessment.